Oligoarticular JIA After Inadequate Response to Conventional DMARD Therapy

In oligoarticular juvenile idiopathic arthritis, when conventional synthetic DMARD (csDMARD) therapy has not achieved the clinical goal of inactive disease, a defined next-line protocol applies. The information below outlines the failure condition and the class of therapy involved in the next step.

Previous Treatment — Failure Condition

The prior treatment line comprised methotrexate (subcutaneous or oral, preferred) or, in order of preference, leflunomide, sulfasalazine, or hydroxychloroquine. Escalation to this protocol is triggered when that line fails to achieve inactive disease.

Next-Line Approach (Partial Overview)

The protocol moves to biologic DMARD therapy — a class of agents with evidence for rapid and sustained improvement in arthritis where csDMARDs have been insufficient. The specific agent selection and full sequencing are set out in the complete structured regimen.

Treatment Targets

The clinical goal is inactive disease and rapid, sustained improvement in arthritis.

Instant Access to Structured Evidence-Based Regimens

References

DOI: 10.1002/art.42037

Biologic DMARDs are strongly recommended if there is inadequate response to or intolerance of NSAIDs and/or IAGCs and at least 1 csDMARD for active oligoarthritis.

There is no preferred bDMARD.

Biologic DMARDs are preferred over combining csDMARDs or switching to a different csDMARD, due to a greater likelihood that bDMARDs will yield rapid and sustained improvement in JIA.

View source ↗